There are 3397 resources available
Discussion
Presenter: All Speakers
Session: Protein degrading cancer drugs: The promises of the new generation
Resources:
Slides
Webcast
Q&A and Discussion
Presenter: All Speakers
Session: Fight the enemy as soon as possible: News and views in the management of early stages colorectal cancer (CRC)
Resources:
Slides
Webcast
2360O - The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC)
Presenter: Bradley McGregor
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA71 - A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
Presenter: Xiuning Le
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Discussion
Presenter: All Speakers
Session: New targets on the horizon
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: David Spiegel
Session: Protein degrading cancer drugs: The promises of the new generation
Resources:
Webcast
Invited Discussant LBA70 and LBA71
Presenter: Yi-Long Wu
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Advancing strategies for cancer immunotherapy
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Next generation diagnostics of blood cancer: An optimistic view on the future of cancer testing
Resources:
Slides
Webcast
Discussion
Presenter: All Speakers
Session: Open questions in the management of mesothelioma
Resources:
Slides
Webcast